Business Daily from THE HINDU group of publications
Thursday, Jun 22, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements


Dr Reddy's launches generic Proscar

Our Bureau

Hyderabad , June 21

Following Teva Pharmaceuticals being awarded 180-day marketing exclusivity for Finasteride, the generic version of Merck's Proscar upon the expiry of patent, Dr Reddy's Laboratories Ltd has announced that it has launched the authorised generic version of Proscar in the US market on Tuesday.

Dr Reddy's had earlier entered into an agreement with Merck, which allows it to distribute and sell generic versions of Proscar (Finasteride 5 mg) and Zocor (Simvastatin), upon the expiry of Merck's patents covered by these products, provided there is an 180-day exclusivity after the patents expiration for either product.

The patent for Zocor is set to expire by weekend. Based on the 180-day marketing exclusivity, Dr Reddy's would take a decision on launching the generic version of Zocor in the US market.

More Stories on : Announcements | Pharmaceuticals | Dr. Reddy's Laboratories Ltd | Channels and Franchises

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Punj Lloyd venture bags Rs 142-cr order


Dr Reddy's launches generic Proscar
Simplex gets sports complex project
Kinetic Motor to issue bonds
Jet-Air Sahara deal in turbulence
M&A with a foreign company
Promoters of Dabur pick up stake in Vishal Mega Mart
GHCL set to buy soda ash unit in Romania for $24 m
HMT to set up tech centres in Zimbabwe
D1 Oils, RPMC in pact for biodiesel manufacture
Essar Oil, US firm tie up for CBM exploration
RIL plans Rs 4,000 cr investment in Bengal
Precision group plans expansion, acquisitions


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line